GetTopicDetailResponse(id=3bf913489f4, topicName=OS, introduction=OS, content=null, image=null, comments=2, allHits=2248, url=https://h5.medsci.cn/topic?id=13489, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=2348, tagList=[TagDto(tagId=2348, tagName=OS)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2164864, encodeId=8ee5216486473, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>：這次會議將對肺癌領(lǐng)域的多項研究數(shù)據(jù)進(jìn)行更新和展示。特別是針對<a href='/topic/show?id=94c265920c' target=_blank style='color:#2F92EE;'>#EGFR突變#</a>陽性非小細(xì)胞肺癌（<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>）的靶向治療，將成為備受關(guān)注的焦點。隨著EGFR酪氨酸激酶抑制劑（<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>）的研發(fā)成功，一代/二代/三代EGFR-TKI已經(jīng)被批準(zhǔn)上市用于EGFR突變的晚期NSCLC治療，<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奧希替尼#</a>是唯一具有確切總生存期（<a href='/topic/show?id=3bf913489f4' target=_blank style='color:#2F92EE;'>#OS#</a>）數(shù)據(jù)的三代EGFR-TKI藥物。, objectTitle=2023 ESMO |【奧希替尼】一線治療地位無可撼動，新方案帶來更多驚喜！, objectType=article, longId=797861, objectId=a343e978611e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20231023/7e658cfe5226459cbf06b6d0e070b22e.jpg, objectUrl=/article/show_article.do?id=a343e978611e, replyNumber=0, likeNumber=179, createdTime=2023-10-25, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a343e978611e, moduleTitle=2023 ESMO |【奧希替尼】一線治療地位無可撼動，新方案帶來更多驚喜！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a343e978611e)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1234204, encodeId=5acf1234204ec, content=<a href='/topic/show?id=a07f82814ec' target=_blank style='color:#2F92EE;'>#腫瘤免疫治療#</a><a href='/topic/show?id=3bf913489f4' target=_blank style='color:#2F92EE;'>#OS#</a><a href='/topic/show?id=9b76198193d' target=_blank style='color:#2F92EE;'>#三陰乳腺癌#</a><a href='/topic/show?id=34b54848271' target=_blank style='color:#2F92EE;'>#帕博利珠單抗#</a>, objectTitle=NEJM重磅：K藥一線治療三陰乳腺癌OS結(jié)果終現(xiàn)！, objectType=article, longId=733028, objectId=c77be33028c3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220722/1658457459652_5490734.jpg, objectUrl=/article/show_article.do?id=c77be33028c3, replyNumber=0, likeNumber=177, createdTime=2022-07-23, rootId=0, userName=病毒獵手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77be33028c3, moduleTitle=NEJM重磅：K藥一線治療三陰乳腺癌OS結(jié)果終現(xiàn)！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c77be33028c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
前往app查看評論內(nèi)容
#ESMO#：這次會議將對肺癌領(lǐng)域的多項研究數(shù)據(jù)進(jìn)行更新和展示。特別是針對#EGFR突變#陽性非小細(xì)胞肺癌（#NSCLC#）的靶向治療，將成為備受關(guān)注的焦點。隨著EGFR酪氨酸激酶抑制劑（#TKI#）的研發(fā)成功，一代/二代/三代EGFR-TKI已經(jīng)被批準(zhǔn)上市用于EGFR突變的晚期NSCLC治療，#奧希替尼#是唯一具有確切總生存期（#OS#）數(shù)據(jù)的三代EGFR-TKI藥物。
